We are proud to announce the release of the 7th World Parkinson Congress abstract issue, showcasing research from scientists, clinicians, healthcare professionals, and advocates from around the world. View the Abstracts here: journals.sagepub.com/toc/pkn…? #wpc2026 #parkinsons

📰 New in JPD: A 10-year analysis (2015-2024) identified 444 Parkinson's drug trials aimed at targeting symptoms or slowing disease progression. 14 drugs have been approved to treat symptoms. Read more: journals.sagepub.com/doi/ful… #ParkinsonsDisease #Parkinsons #parkinsonsresearch

📢 Neurology researchers - want to strengthen your publishing skills? Join our webinar Mastering the Neurology Publication Journey (17 June, 4PM BST) to learn manuscript writing, peer review, and editor expectations. Register now: ow.ly/Vvvs50Z0bsg #Neurology #Webinar

💡 New blog post in JPD: From One Size Fits All to Gaining Consensus that Personalized Medicine is the Future, by Susanne J. Bowen Read here: linkedin.com/pulse/from-one-… #ParkinsonsDisease #parkinsonsresearch #parkinsonsawareness #parkinsons

📕 NEW ISSUE. Featuring Review articles on high intensity interval training (HIIT) for Parkinson's, and the central cholinergic system as a therapeutic target in Parkinson's. Explore the issue: journals.sagepub.com/toc/pkn… #parkinsonsdisease #parkinsonsresearch #parkinsons

📢 New in JPD: Abstracts from the 2026 Planning for Prevention of Parkinson’s Trial Design Forum. Held for the advancement of trial design research for Parkinson's prevention. Read it free: journals.sagepub.com/doi/ful… #WorldParkinsonCongress #ParkinsonsDisease #ParkinsonsResearch

A special series of Review articles tied to #WPC2026 is now available in @journal_pd covering topics including stem cell treatments, AI, clinical trial design, resilience, and more. New papers are still being added. Read here: journals.sagepub.com/topic/c…

JPD is attending the World Parkinson's Congress in Phoenix with a booth in the exhibit hall. Visit us for questions on publishing your paper, or to discuss innovative ideas for JPD coverage: Booth #608 at the wpc2026.org/ #WPC2026 #journal_pd #parkinsons #PDResearch

We are proud to announce an ongoing collection of Review articles coming from the #WPC2026. Topics include: clinical trial design, synaptic vesicle dysfunction, stem cells, AI, resilience and reserve, and dietary supplements. Read at: tinyurl.com/WPCissue #parkinsons #WPC2026

Webinar: Pesticides and Parkinson's, 3 June 2026, 5-6pm BST, 12-1pm ET In this webinar, Professor Tilo Kunath and an expert panel will discuss pesticides, their link to Parkinson's, and what to be aware of when exposed to pesticides. Register here: eventbrite.co.uk/e/webinar-p…

Stem cells and Parkinson’s: hope, hype, and hard truths. Stem cells are special cells that can develop into many different cell types, including dopamine producing brain cells. Stamper, Bulstrode and Barker describe in a new paper in the Journal of Parkinson’s Disease how stem cell therapies for Parkinson’s disease have evolved, and where science meets misconception. Key points: - Dopamine cell therapy aims to replace lost dopamine-producing neurons, however it is not a cure because it does not stop the underlying disease process. - Early and current clinical trials show modest and variable benefits, w/ ongoing challenges in cell survival, delivery and integration into brain circuits. - Safety signals so far are encouraging, however long term risks, optimal patient selection and dosing strategies remain to be fully defined. My take: This is a thoughtful and grounded review. I had the honor of interviewing Roger Barker for our book the Parkinson's Plan. Stem cell therapy for Parkinson’s disease is real science, not science fiction, however it is also not ready to meet the expectations that frequently circulate online. Progress is steady, and the field is learning from each step forward and each misstep. Here are 5 points that resonated w/ me: 1- Stem cell therapies are designed to repair dopamine systems, not to cure Parkinson’s disease. 2- Results so far show signals of benefit, however they are inconsistent and not yet transformative. 3- Safety appears reassuring in early trials, however long term follow up is essential before broad adoption. 4- Not every patient will be an ideal candidate, and timing of therapy will likely matter. 5- The future may depend on improving delivery, survival of transplanted cells and integrating therapies w/ precision medicine approaches. journals.sagepub.com/doi/ful… #parkinson @ParkinsonDotOrg @journal_PD

A new @aiprognosis -related publication has been published in the @journal_PD: “ChatGPT knows my Parkinson’s”: Perspectives of people with Parkinson’s disease on use of generative AI 🔗 journals.sagepub.com/doi/10.… #GenerativeAI #DigitalHealth #Parkinsons

📰 Highly popular Review article in JPD: Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same, by Borghammer, Okkels, and Weintraub Read it completely free here: journals.sagepub.com/doi/ful…

📰 NEW: Review article in JPD Harnessing artificial intelligence: Revolutionizing clinical care for Parkinson's disease, by William J Marks, Jr Read the full Review here: journals.sagepub.com/doi/10.… #ParkinsonsDisease #parkinsonsresearch #parkinsons #AI

🔦 Spotlighting our Clinical Trial Highlights section! A collection of articles that engage with the clinical trial landscape to support open discourse and progress. All content is free to read, download and share! Explore the collection here: journals.sagepub.com/page/pk…

Trending paper: Parkinson’s Disease Is Predominantly an Environmental Disease, by neurologist Ray Dorsey and JPD's Editor-in-Chief Bas Bloem. Read it free here: journals.sagepub.com/doi/10.… #ParkinsonsDisease #parkinsonsresearch #parkinsonsawareness #parkinsons